Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Chief Operating Officer | February 18, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed March 03, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,128,312 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-18 · Grant · Acquired 49,102 · Balance 1,144,687 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Row 2 · 2026-02-18 · Tax withholding · Disposed 16,375 · Balance 1,128,312 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 120,267 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · derivative · entry 4 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,267 Underlying: Class A Common Stock · 120,267 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 16,212 | $3.84 | $62,254.08 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,127,985 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 48,612 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,197 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 210,937 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,095,585 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 16,375 | $3.84 | $62,880.00 |
DisclosureSEC source: 0002064832-26-000089 · form4a.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,128,312 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 49,102 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000089 · form4a.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,687 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 15,352 | $3.73 | $57,262.96 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 4 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 884,648 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 15,617 | $3.73 | $58,251.41 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 28,331 | $3.73 | $105,674.63 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,617 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 5,114 | $3.73 | $19,075.22 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 943,948 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:54 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 190,475 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003233 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,475 Underlying: Class A Common Stock · 190,475 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:54 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 184,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003233 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,062 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 790 | $3.70 | $2,923.00 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 4 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,926 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,883 | $3.70 | $14,367.10 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 765,716 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 25,739 | $3.70 | $95,234.30 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,599 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 13,744 | $3.70 | $50,852.80 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 795,338 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,497 | $2.80 | $6,991.60 |
DisclosureSEC source: 0001062993-24-007937 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 809,082 Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 152,250 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001062993-24-007462 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 152,250 shares Expires 2024-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 152,250 | $1.18 | $179,655.00 |
DisclosureSEC source: 0001062993-24-007462 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 811,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 338,674 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004311 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,674 Underlying: Class A Common Stock · 338,674 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 187,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004311 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659,329 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 791 | $3.48 | $2,752.68 |
DisclosureSEC source: 0001062993-24-003760 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,011 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 4,608 | $3.68 | $16,957.44 |
DisclosureSEC source: 0001062993-24-003760 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,802 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 24,925 | $3.68 | $91,724.00 |
DisclosureSEC source: 0001062993-24-003760 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,410 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,678 | $2.13 | $5,704.14 |
DisclosureSEC source: 0001062993-23-008505 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,335 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 388,654 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004889 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,654 Underlying: Class A Common Stock · 388,654 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 327,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004889 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,013 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 936 | $2.75 | $2,574.00 |
DisclosureSEC source: 0001062993-23-004056 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,627 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 4,599 | $2.92 | $13,429.08 |
DisclosureSEC source: 0001062993-23-004056 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,563 Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,497 | $7.89 | $19,701.33 |
DisclosureSEC source: 0001062993-22-009807 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,162 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:55 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 937 | $7.78 | $7,289.86 |
DisclosureSEC source: 0001062993-22-004800 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,659 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:55 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 125,522 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001062993-22-004800 · form4.xml · derivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,522 Underlying: Class A Common Stock · 125,522 shares Expires 2032-02-15 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:55 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 52,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004800 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,596 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 23:01 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,450 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001661181-21-000068 · edgar.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,450 shares Expires 2021-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 23:01 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 30,450 | $1.44 | $43,848.00 |
DisclosureSEC source: 0001661181-21-000068 · edgar.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reporting person transferred 60,900 shares of Class A Common Stock held by the reporting person to his former spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his former spouse. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:47 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,497 | $19.83 | $49,515.51 |
DisclosureSEC source: 0000899243-21-014960 · doc4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,120 Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:38 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 82,556 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0001661181-21-000027 · edgar.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,556 Underlying: Class A Common Stock · 82,556 shares Expires 2031-02-16 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:38 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 10,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000027 · edgar.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,617 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 11:47 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 224,185 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001661181-20-000014 · edgar.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,185 Underlying: Class A Common Stock · 224,185 shares Expires 2030-04-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 11:47 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 34,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-20-000014 · edgar.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,835 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 101,500 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000035 · edgar.xml · derivative · entry 5 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,500 Underlying: Common Stock · 101,500 shares Expires 2027-05-04 F9 · price: Received in connection with the Merger in exchange for an option to acquire 50,000 shares of common stock of Organogenesis for $7.01 per share. F8 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 142,100 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000035 · edgar.xml · derivative · entry 4 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,100 Underlying: Common Stock · 142,100 shares Expires 2027-05-04 F7 · price: Received in connection with the Merger in exchange for an option to acquire 70,000 shares of common stock of Organogenesis for $7.01 per share. F6 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 152,250 | Not disclosed Strike: $1.18 | Not disclosed |
DisclosureSEC source: 0001661181-18-000035 · edgar.xml · derivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,250 Underlying: Common Stock · 152,250 shares Expires 2024-04-10 F5 · price: Received in connection with the Merger in exchange for an option to acquire 75,000 shares of common stock of Organogenesis for $2.38 per share. F4 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2015. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 30,450 | Not disclosed Strike: $1.44 | Not disclosed |
DisclosureSEC source: 0001661181-18-000035 · edgar.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,450 Underlying: Common Stock · 30,450 shares Expires 2021-12-06 F3 · price: Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for $2.92 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantCommon Stock | 121,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001661181-18-000035 · edgar.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,800 F1 · price: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 60,000 shares of common stock of Organogenesis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.